BioCentury
ARTICLE | Finance

Cidara's antimicrobial reunion

Seasoned antiinfectives team at Cidara aiming to disrupt antifungal market

July 14, 2014 7:00 AM UTC

Investors in Cidara Therapeutics Inc.'s $32 million series A round are hoping for a repeat performance by a management team with a track record of exits in the infectious disease space.

5AM Ventures led the round and was joined by Aisling Capital, Frazier Healthcare and InterWest Partners...